La cadena de opciones muestra datos clave de las opciones de acciones de BriaCell Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para BriaCell Therapeutics..

BriaCell Therapeutics (NASDAQ:BCTX) Bolsa, Cadena de Opciones

BriaCell Therapeutics

BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

Pre-Market Outlook

Markets

Movers

ACON

AEON

BCTX

CPHC

EKSO

Sunrise New Energy Co., Ltd - Ordinary Shares

EPOW

KITT

LDTC

MBOT

MEGL

MNSO

NSTS

SPPL

WFCF

Explora los mayores movimientos en el premercado con ganancias superiores al 100% y pérdidas significativas antes de la apertura.

Acciones de Smart Share Global se disparan un 44%; 20 acciones que se mueven en el premercado

BriaCell Therapeutics Corp. - Common Shares

BriaCell Therapeutics Corp

The most oversold stocks in the utilities sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Sunnova Energy International Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>)</h3>
<ul>
<li>On April 1, Sunnova named Robyn Liska as interim CFO. &#8220;Robyn has deep industry knowledge and a proven record of driving financial transformation,&#8221; said Paul Mathews, Sunnova Chief Executive Officer. &#8220;Her expertise will be invaluable as we continue to work to stabilize our foundation, sharpen our execution, and position Sunnova to succeed in today&#8217;s evolving solar energy market.&#8221; The company's stock fell around 44% over the past month and has a 52-week low of $0.25.</li>
<li>RSI Value: 26.3</li>
<li>NOVA Price Action: Shares of Sunnova Energy fell 11.3% to close at $0.33 on Tuesday.</li>
<li>Edge Stock Ratings: 0.48 Momentum score with Value at 89.09. </li>
</ul>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/NOVA"><img loading="lazy" decoding="async" width="427" height="177" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02035323/image-18.png" alt="" class="wp-image-852699" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02035323/image-18.png 427w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02035323/image-18-300x124.png 300w" sizes="(max-width: 427px) 100vw, 427px" /></a></figure>
<h3 class="wp-block-heading">Cadiz Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDZI#NASDAQ">CDZI</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On March 7, Cadiz Inc. announced a $20 million registered direct offering. The offering involves the sale of 5,715,000 shares of its common stock at $3.50 per share. The company expects to use the net proceeds for capital and other expenses related to the development and construction of its Mojave Groundwater Bank project.. The company's stock fell around 28% over the past month and <a href="https://www.benzinga.com/quote/CDZI">has a 52-week low</a> of $2.12.</li>
<li>RSI Value: 29</li>
<li>CDZI Price Action: Shares of Cadiz gained 0.7% to close at $2.95 on Tuesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0402">CDZI stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0402"><img loading="lazy" decoding="async" width="918" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02035456/image-19.png" alt="" class="wp-image-852702" style="width:546px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02035456/image-19.png 918w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02035456/image-19-300x270.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02035456/image-19-768x692.png 768w" sizes="(max-width: 918px) 100vw, 918px" /></a></figure>
<h3 class="wp-block-heading">Spruce Power Holding Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPRU#NYSE">SPRU</a>)</h3>
<ul>
<li>On March 31, Spruce Power Holding reported a quarterly loss of 29 cents per share, versus a year-ago loss of $1.60 per share. &#8220;In this time of heightened uncertainty across the residential solar market, Spruce offers investors greater stability and predictability given that our business is predicated on generating long-term contracted cash flows from existing solar assets through operational efficiencies, maintenance and superior asset management,&#8221; said Chris Hayes, Spruce&#8217;s Chief Executive Officer. The company's stock fell around 20% over the past five days and has a 52-week<a href="https://www.benzinga.com/quote/SPRU"> low of $2.08.</a></li>
<li>RSI Value: 25.4</li>
<li>SPRU Price Action: Shares of Spruce Power fell 12% to close at $2.12 on Tuesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0402">SPRU shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0402"><img loading="lazy" decoding="async" width="870" height="820" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02035518/image-1-3.png" alt="" class="wp-image-852703" style="width:516px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02035518/image-1-3.png 870w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02035518/image-1-3-300x283.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02035518/image-1-3-768x724.png 768w" sizes="(max-width: 870px) 100vw, 870px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a> 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44584246/wall-streets-most-accurate-analysts-give-their-take-on-3-consumer-stocks-delivering-high-dividend-yields-6">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

News

Trading Ideas

CDZI

NOVA

Spruce Power Holding Corporation Class A Common Stock

SPRU

Top 3 Utilities Stocks That May Rocket Higher This Quarter

Winnebago Industries has repaid a total of $159 million of debt to date in fiscal 2025.

Winnebago Reports Settlement In Cash Of Remaining $59.3M Of 1.50% Unsecured Convertible Senior Notes Due April 1, 2025

ALLE

Allegion Acquires Trimco Hardware To Expand Commercial And Institutional Door Hardware Portfolio

Laboratory Corporation Of America Holdings

Labcorp Reveals Nationwide Launch Of pTau-217/Beta Amyloid 42 Ratio, New Blood-based Biomarker Test To Aid In Diagnosis Of Alzheimer's Disease

CRVO

CervoMed To Present New Data On Neflamapimod's Impact On DLB At 19th International Conference On Alzheimer's and Parkinson's Disease

<a href="https://www.reuters.com/markets/commodities/bhp-considered-spinning-off-iron-ore-coal-divisions-2025-04-02/" title="https://www.reuters.com/markets/commodities/bhp-considered-spinning-off-iron-ore-coal-divisions-2025-04-02/">https://www.reuters.com/markets/commodities/bhp-considered-spinning-off-iron-ore-coal-divisions-2025-04-02/</a>

Reuters Reported BHP Considered Spinning Off Iron Ore, Coal Divisions

Telsey Advisory Group analyst Dana Telsey maintains Capri Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>) with a Market Perform and maintains $23 price target.

Price Target

Analyst Ratings

CPRI

Telsey Advisory Group Maintains Market Perform on Capri Holdings, Maintains $23 Price Target

As markets brace for the impact of <a href="https://www.benzinga.com/25/04/44589523/trumps-liberation-day-tariff-plan-could-ignite-global-trade-shakeup-betting-markets-price-in-the-pain">President Trump&#8217;s tariff announcements</a>, experts point to regulatory clarity as bullish catalyst, while a looming correction in equities remains the most <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44598254/bitcoin-is-in-a-mini-bear-market-says-10x-research">prominent downside risk.</a>
What Happened Despite a global macro backdrop filled with uncertainties—from proposed sweeping U.S. tariffs to stubborn inflation and elevated rates—digital assets have shown remarkable resilience.
But analysts and industry leaders warn that the current rally may be masking deeper tensions.
Speaking with Benzinga, Mike Cahill, CEO of Douro Labs, a key contributor to the Pyth Network (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PYTH</a>), believes the optimism in markets is short-term in nature.
"Markets rallying into the tariff announcement reflect a classic case of short-term optimism winning out over long-term uncertainty," he said. 
For Cahill, the real story isn't about euphoria or complacency, but selective positioning by experienced traders. "Calling it ‘nothing ever happens' is premature," he added.
Cahill sees regulatory clarity, particularly around stablecoins and tokenized assets, as the clearest positive catalyst ahead. 
"That's the green light institutions are waiting for to go all in," he said. 
On the flip side, he warns that a macro shock, driven by high rates and escalating trade tensions, could rapidly sap liquidity and hurt sentiment across risk assets, including crypto.
Gadi Chait, Investment Manager at Xapo Bank, framed the recent market drop as part of a broader tug-of-war between long-term conviction and short-term anxiety.
"Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) investors have been bracing for today's announcement, so a price drop comes as no surprise," he said, referring to anticipated trade actions from the Trump administration. 
For Chait, Bitcoin remains a long-term bet on sovereignty and scarcity, unaffected by momentary volatility. "We've been here before, and we'll likely be here again, but Bitcoin's long-term trajectory remains undeniable."
The price of Bitcoin has recently fluctuated between $76,600 and $94,500, stabilizing around $85,000 on Tuesday.
Chait cautioned that a break below $76,600 could shift sentiment decisively, but until then, the broader range remains intact.
Also Read: <a href="https://www.benzinga.com/top-stories/25/04/44590297/coinbase-ceo-brian-armstrong-advocates-for-stablecoins-consumers-deserve-a-bigger-piece-of-the-pie">Coinbase CEO Brian Armstrong Advocates For Stablecoins: &#8216;Consumers Deserve A Bigger Piece Of The Pie&#8217;</a>
Ryan Lee, Chief Analyst at Bitget Research, emphasized that geopolitical tension could actually amplify Bitcoin's appeal. 
"Trump's proposed tariffs potentially supercharge Bitcoin's appeal by shaking confidence in fiat currencies like the U.S. dollar," he said. 
Lee also noted that stagflation risk—rising prices without accompanying growth—might drive more traders toward decentralized assets as traditional safe havens falter. 
"We'd expect a spike in Bitcoin demand—perfect for our users to ride the wave using spot, futures, or our staking options," Lee added.
Why It Matters: Still, not all analysts are interpreting the current moment as a full-blown crypto bull run.
Xia Yumin, CTO at Galxe, noted that gains in the space have largely been isolated to Bitcoin, with Ethereum and most altcoins lagging. 
"If we examine the market at a micro level, the significant gains are mainly concentrated in Bitcoin," Yumin observed. 
While Bitcoin may challenge prior highs in the coming quarter, Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), he said, will need more technical or sentiment-driven momentum to break out.
Looking ahead, Yumin identified macroeconomic policy—specifically U.S. interest rates—as a defining force for crypto valuations. 
"Interest rate cuts as anticipated during each FOMC meeting will continue to elevate BTC's valuation as a scarce asset," he said.
He also pointed to a clear and present risk: a downturn in U.S. equities. "In a crypto market that currently lacks its own independent narrative, any downturn in equities will likely drag crypto down with it."
As traders await more details on the Trump administration's "reciprocal tariffs," estimated to impact nearly $3 trillion in imports, the financial markets <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44591699/eric-trump-hails-bitcoin-as-one-of-the-greatest-stores-of-value">are sending mixed signals.</a> 
U.S. bond yields remain elevated, and expectations for a Fed rate cut remain tepid. 
The CME FedWatch tool currently shows markets pricing in an 85.5% chance of the <a href="https://www.benzinga.com/25/04/44602347/us-stock-futures-slip-ahead-of-liberation-day-tariffs-announcement-more-uncertainty-means-higher-risk-premia-says-analyst">Fed holding rates steady through May.</a>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44587813/titandex-ceo-chris-chung-advocates-social-consensus-for-crypto-ethics-sees-bright-future-for-defi">Crypto Industry Needs To Enforce Ethical Norms, TitanDex CEO Chris Chung Says</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$PYTH

Bitcoin Braces For Trump Tariff Announcement: 'Short-Term Optimism' Has The Upper Hand, Experts Say

FYE26 Outlook
Our outlook for the year ending January 31, 2026 ("FYE26" and "Fiscal 2026") is as follows:
<ul>
<li>Revenue: $392 million at the midpoint with a range of +/-2%, representing approximately 12% growth from previous year revenue.</li>
<li>Adjusted EBITDA: Approximately $43 million at the midpoint of our revenue outlook.</li>
<li>Non-GAAP Diluted EPS: $0.16 at the midpoint of our revenue outlook.</li>
</ul>

Guidance

CGNT

Cognyte Expects FY26 Revenue Of $392M At Midpoint With Range Of +/-2% Vs. $373.46M Est, Adj EPS Of $0.16 Vs. $0.14 Est

With this transition, Avanos will manage all sales, support, and distribution directly, reinforcing its dedication to delivering high-quality enteral feeding solutions.
For the past 29 years, Vygon UK, a supplier of surgical and medical devices has been a valued distributor of the MIC&#x2A; and MIC-KEY family of products.

AVNS

Avanos Medical Plans To Take Direct Responsibility For Sales And Distribution Of Its MIC-KEY Enteral Feeding Products In UK, Effective July 25, 2025

Norwegian Cruise Line Holdings &nbsp;and NCL Corporation Ltd., a subsidiary of the Company ("NCLC"), announce that NCLC has entered into individually negotiated note exchange agreements with certain existing holders (the "Holders") of NCLC's 5.375% Exchangeable Senior Notes due 2025 (the "2025 Notes"), pursuant to which NCLC and the Holders have agreed to exchange (the "Exchange") $285,425,000 in aggregate principal amount of the Holders' 2025 Notes for (i) $285,425,000 in aggregate principal amount of NCLC's newly issued 0.875% Exchangeable Senior Notes due 2030 (the "2030 Notes") and (ii) an aggregate cash payment (the "Cash Payment") of $51,624,820, plus accrued and unpaid interest on the 2025 Notes to be exchanged to, but excluding, the closing date of the Exchange. The Cash Payment will be equal to the proceeds from the concurrent Equity Offering, as described below, and represents the remainder of NCLC's exchange obligation in excess of the aggregate principal amount of the 2025 Notes to be exchanged.
Concurrently, the Company announces a registered direct offering of 2,708,533 ordinary shares to the Holders at a price of $19.06 per share (the "Equity Offering" and together with the Exchange, the "Transactions"). The Company expects to use the proceeds from the Equity Offering to make the Cash Payment.

NCLH

NCLH To Cut Fully Diluted Share Count By 12.5M Following Note Exchange And Equity Sale

Telsey Advisory Group analyst Dana Telsey maintains PVH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) with a Outperform and maintains $90 price target.

Telsey Advisory Group Maintains Outperform on PVH, Maintains $90 Price Target

PROP

Prairie Operating Co. Launches 11-Well Development Program At Rusch Pad In Colorado's DJ Basin

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Aquestive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQST#NASDAQ">AQST</a>) with a Buy and maintains $10 price target.

Reiteration

AQST

HC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $10 Price Target

CRGO

Freightos Expands With Air Europa Partnership, Enhancing Digital Freight Booking Across Spain-Latin America Routes

Telsey Advisory Group analyst Dana Telsey maintains Levi Strauss (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) with a Outperform and maintains $23 price target.

LEVI

Telsey Advisory Group Maintains Outperform on Levi Strauss, Maintains $23 Price Target

Financial Outlook
BlackBerry is providing the following guidance for the first fiscal quarter and the full fiscal year 2026 (ending February 28, 2026).
<figure class="table"> 
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>Q1 FY26</td>
<td>Full fiscal year FY26</td>
</tr>
<tr>
<td>Total BlackBerry revenue:</td>
<td>$107 - $115 million</td>
<td>$504 - $534 million</td>
</tr>
<tr>
<td>QNX revenue:</td>
<td>$51 - $55 million</td>
<td>$250 - $270 million</td>
</tr>
<tr>
<td>Secure Communications revenue:</td>
<td>$50 - $54 million</td>
<td>$230 - $240 million</td>
</tr>
<tr>
<td>Licensing revenue:</td>
<td>Approximately $6 million</td>
<td>Approximately $24 million</td>
</tr>
<tr>
<td>QNX segment adjusted EBITDA:</td>
<td>$2 - $6 million</td>
<td>$55 - $60 million</td>
</tr>
<tr>
<td>Secure Communications segment</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>adjusted EBITDA:</td>
<td>$3 - $6 million</td>
<td>$34 - $44 million</td>
</tr>
<tr>
<td>Licensing segment adjusted EBITDA:</td>
<td>Approximately $5 million</td>
<td>Approximately $20 million</td>
</tr>
<tr>
<td>Adjusted Corporate Costs:</td>
<td>Approximately $10 million</td>
<td>Approximately $40 million</td>
</tr>
<tr>
<td>Total Company adjusted EBITDA:</td>
<td>Breakeven - $7 million</td>
<td>$69 - $84 million</td>
</tr>
<tr>
<td>Non-GAAP basic EPS:</td>
<td>($0.01) - Breakeven</td>
<td>$0.08 - $0.10</td>
</tr>
<tr>
<td>Operating cash flow (usage)</td>
<td>($20) - ($30) million</td>
<td>Approximately $35 million</td>
</tr>
</tbody>
</table>
</figure>

BlackBerry Now Expects FY26 Total Revenue Of $504M-$534M Vs $546.34M Est, Adj EPS Of $0.08-$0.10 Vs $0.10 Est

HC Wainwright &amp; Co. analyst Matthew Caufield maintains Mineralys Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLYS#NASDAQ">MLYS</a>) with a Buy and raises the price target from $30 to $42.

MLYS

HC Wainwright & Co. Maintains Buy on Mineralys Therapeutics, Raises Price Target to $42

Telsey Advisory Group analyst Dana Telsey maintains Macy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) with a Market Perform and maintains $15 price target.

Telsey Advisory Group Maintains Market Perform on Macy's, Maintains $15 Price Target

As a result, the company expects first quarter 2025 Adjusted Profit Before Tax&nbsp;in a range of $92.3 to $97.3 million (Q1 2024: $67.7 million).
 &nbsp;

Comments

BriaCell Therapeutics

BriaCell Therapeutics (BCTX) Opciones

BriaCell Therapeutics (NASDAQ:BCTX) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL